STOCK TITAN

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cara Therapeutics, Inc. (CARA) to present at the 23rd Annual Needham Virtual Healthcare Conference. The President and CEO will discuss the company's innovative pruritus treatment approach. Webcast details are available on the company's website.
Positive
  • None.
Negative
  • None.

STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide. For more information, visit www.CaraTherapeutics.com and follow the company on X (Twitter), LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com


FAQ

When will Cara Therapeutics present at the 23rd Annual Needham Virtual Healthcare Conference?

Cara Therapeutics will present on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

What is the focus of Cara Therapeutics' treatment approach?

Cara Therapeutics focuses on improving the lives of patients suffering from pruritus.

Where can the webcast of the presentation be accessed?

The webcast can be accessed under 'Events & Presentations' in the Investors section of the company's website at www.CaraTherapeutics.com.

How long will the archived webcast recording be available?

The archived webcast recording will be available on the Cara website for approximately 30 days.

Cara Therapeutics, Inc.

NASDAQ:CARA

CARA Rankings

CARA Latest News

CARA Stock Data

16.00M
54.85M
15.75%
32.71%
1.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
STAMFORD